• 1
    Rider GL, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 20: 94353.
  • 2
    Rider GL, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Bailliere's Clin Rheumatol 2000; 14: 3754.
  • 3
    Rennebohm RM. Juvenile dermatomyositis. Pediatr Ann 2002; 31: 42633.
  • 4
    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 22139.
  • 5
    Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. The Childhood Myositis Assessment Scale (CMAS) is a validated measure of physical function and muscle strength in the juvenile idiopathic inflammatory myopathies (JIIM). Arthritis Rheum 2002; 46 Suppl: S2167.
  • 6
    Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001; 40: 126273.
  • 7
    Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25: 1198204.